throbber
Case 1:21-cv-01159-UNA Document 1 Filed 08/10/21 Page 1 of 12 PageID #: 1
`
`ANTHONY MORGAN,
`
`
`Plaintiff,
`
`v.
`
`UNITED STATES DISTRICT COURT
`DISTRICT OF DELAWARE
`
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`)
`
`
`
`
`Case No. _____________
`
`COMPLAINT FOR VIOLATIONS OF
`THE FEDERAL SECURITIES LAWS
`
`
`JURY TRIAL DEMANDED
`
`
`
`KINDRED BIOSCIENCES, INC., LYNDON
`LIEN, NANXI LIU, HERBERT D.
`MONTGOMERY, RAYMOND TOWNSEND,
`ERVIN VESZPREMI, DENISE M. BEVERS,
`RICHARD CHIN, and JOSEPH S.
`MCCRACKEN,
`
`
`Defendants.
`
`
`Plaintiff Anthony Morgan (“Plaintiff”), by and through his undersigned counsel, for his
`
`
`
`
`
`complaint against defendants, alleges upon personal knowledge with respect to himself, and upon
`
`information and belief based upon, inter alia, the investigation of counsel as to all other allegations
`
`herein, as follows:
`
`NATURE THE ACTION
`
`1.
`
`Plaintiff brings this action against Kindred Biosciences, Inc. (“Kindred” or the
`
`“Company”) and its corporate directors for violating Sections 14(a) and 20(a) of the Securities
`
`Exchange Act of 1934 (the “Exchange Act”), 15 U.S.C. §§ 78n(a), 78t(a), and U.S. Securities and
`
`Exchange Commission (“SEC”) Rule 14a-9, 17 C.F.R. § 240.14a-9. By the action, Plaintiff seeks to
`
`enjoin the vote on a proposed transaction pursuant to which Kindred will merge with Elanco Animal
`
`Health Incorporated (“Elanco”) through Elanco’s subsidiary Knight Merger Sub, Inc. (“Merger Sub”)
`
`(the “Proposed Transaction”).1
`
`
`1 Non-party Elanco is an Indiana corporation with its principal executive offices located at 2500
`Innovation Way, Greenfield, IN 46140. Elanco’s common shares trade on the New York Stock
`Exchange under the symbol “ELAN.” Non-party Merger Sub is a Delaware corporation and wholly
`owned subsidiary of Elanco.
`
`

`

`Case 1:21-cv-01159-UNA Document 1 Filed 08/10/21 Page 2 of 12 PageID #: 2
`
`2.
`
`On June 16, 2021, Kindred and Elanco jointly announced their entry into an
`
`Agreement and Plan of Merger dated June 15, 2021 (the “Merger Agreement”) to sell Kindred to
`
`Elanco. Under the terms of the Merger Agreement, each Kindred stockholder will receive $9.25 in
`
`cash for each share of Kindred common stock they own (the “Merger Consideration”).2
`
`3.
`
`On July 21, 2021, Kindred filed a Schedule 14A Definitive Proxy Statement (the
`
`“Proxy Statement”) with the SEC. The Proxy Statement, which recommends that Kindred
`
`stockholders vote in favor of the Proposed Transaction, omits or misrepresents material information
`
`necessary and essential to that decision. The failure to adequately disclose such material information
`
`violates Sections 14(a) and 20(a) of the Exchange Act as Kindred stockholders need such information
`
`to make a fully informed decision whether to approve the Proposed Transaction.
`
`4.
`
`It is imperative that the material information omitted from the Proxy Statement is
`
`disclosed to the Company’s stockholders prior to the forthcoming stockholder vote so that they can
`
`properly exercise their corporate suffrage rights.
`
`5.
`
`For these reasons, and as set forth in detail herein, Plaintiff seeks to enjoin Defendants
`
`from taking any steps to consummate the Proposed Transaction unless and until the material
`
`information discussed below is disclosed to the Company’s stockholders or, in the event the Proposed
`
`Transaction is consummated.
`
`JURISDICTION AND VENUE
`
`6.
`
`This Court has jurisdiction over the claims asserted herein for violations of Sections
`
`14(a) and 20(a) of the Exchange Act and SEC Rule 14a-9 promulgated thereunder pursuant to Section
`
`27 of the Exchange Act, 15 U.S.C. § 78aa, and 28 U.S.C. § 1331 (federal question jurisdiction).
`
`7.
`
`This Court has jurisdiction over the defendants because each defendant is either a
`
`
`2 The approximate value of the Proposed Transaction is $440 million.
`
`2
`
`

`

`Case 1:21-cv-01159-UNA Document 1 Filed 08/10/21 Page 3 of 12 PageID #: 3
`
`corporation that conducts business in and maintains operations within this District or is an individual
`
`with sufficient minimum contacts with this District so as to make the exercise of jurisdiction by this
`
`Court permissible under traditional notions of fair play and substantial justice.
`
`8.
`
`Venue is proper in this District pursuant to 28 U.S.C. § 1391 because defendants are
`
`found or are inhabitants or transact business in this District.
`
`THE PARTIES
`
`9.
`
`Plaintiff is, and has been at all times relevant hereto, a continuous stockholder of
`
`Kindred.
`
`10.
`
`Defendant Kindred is a Delaware corporation, with its principal executive offices
`
`located at 1555 Bayshore Highway, Suite 200, Burlingame, California 94010. The Company is a
`
`biopharmaceutical company focused on developing novel pet therapeutics. Kindred’s common stock
`
`trades on The Nasdaq Global Select Market under the ticker symbol “KIN.”
`
`11.
`
`Defendant Lyndon Lien (“Lien”) has been a director of the Company since February
`
`5, 2021.
`
`12.
`
`Defendant Nanxi Liu (“Liu”) has been a director of the Company since February 5,
`
`2021.
`
`13.
`
`Defendant Herbert D. Montgomery (“Montgomery”) has been a director of the
`
`Company since April 15, 2016.
`
`14.
`
`Defendant Raymond Townsend (“Townsend”) has been a director of the Company
`
`since November 11, 2013.
`
`15.
`
`Defendant Ervin Veszprémi (“Veszprémi”) has been a director of the Company since
`
`February 15, 2013.
`
`16.
`
`Defendant Denise M. Bevers (“Bevers”) is a co-founder of the Company and has been
`
`a director since October 19, 2018. Defendant Bevers previously served as the Company’s Chief
`
`3
`
`

`

`Case 1:21-cv-01159-UNA Document 1 Filed 08/10/21 Page 4 of 12 PageID #: 4
`
`Operating Officer (“COO”) from October 2012 to July 31, 2020, Secretary from November 2013 to
`
`July 31, 2020, and President from October 19, 2018 to July 31, 2020.
`
`17.
`
`Defendant Richard Chin (“Chin”) is a co-founder of the Company, has been Chief
`
`Executive Officer (“CEO”) since October 2012, President from October 2012 to October 2018, and
`
`since July 31, 2020, and is and has been a director of the Company at all relevant times.
`
`18.
`
`Defendant Joseph S. McCracken (“McCracken”) has been a director of the Company
`
`since April 20, 2018.
`
`19.
`
`Defendants identified in paragraphs 11-18 are referred to herein as the “Board” or the
`
`“Individual Defendants.”
`
`The Proposed Transaction
`
`SUBSTANTIVE ALLEGATIONS
`
`20.
`
`On August 5, 2020, Kindred and Elanco jointly announced, in relevant part:
`
`GREENFIELD, Ind. and SAN FRANCISCO (June 16, 2021) – Elanco Animal Health
`Incorporated (NYSE: ELAN) and Kindred Biosciences, Inc. (KindredBio, NASDAQ:
`KIN) today announced the parties have entered into a definitive agreement for Elanco
`to acquire KindredBio, a biopharmaceutical company focused on developing novel pet
`therapeutics based on validated human targets. The acquisition further accelerates
`Elanco’s expansion in the attractive pet health market, particularly advancing Elanco’s
`presence in the fast-growing billion-dollar dermatology category.
`
`KindredBio brings three potential dermatology blockbusters expected to launch
`through 2025, as well as a number of additional R&D programs for other chronic
`disorders and unmet needs, including canine parvovirus. KindredBio’s innovative
`pipeline – added to Elanco’s own organic efforts – meaningfully augments Elanco’s
`ability to launch products, gain share, and grow in the dermatology market through
`fully accretive revenue dollars. Elanco anticipates the combination will add
`approximately $100 million to its previously stated innovation revenue expectation of
`$500 million to $600 million by 2025, with significant opportunity beyond the period.
`
`“This highly complementary combination is focused in one of the most exciting spaces
`in pet health, and one where we see a strategic imperative to build a differentiated
`competitive offering,” said Jeff Simmons, president and CEO of Elanco. “It further
`accelerates our mix shift into pet health and advances our IPP strategy. Ultimately,
`we believe the combination positions Elanco to bring innovative solutions to
`veterinarians and pet owners in areas of unmet or under-served medical needs, fueling
`
`4
`
`

`

`Case 1:21-cv-01159-UNA Document 1 Filed 08/10/21 Page 5 of 12 PageID #: 5
`
`continued growth in the exciting pet therapeutic category and creating sustainable
`long-term value for shareholders.”
`
`The acquisition agreement builds on Elanco’s existing relationship with KindredBio,
`which began with licensing the global commercial rights of KindredBio’s late-stage
`treatment for canine parvovirus, and continues Elanco’s proven approach as an
`innovation partner of choice.
`
`“From the beginning, we have been focused at KindredBio on bringing the best
`medicines to our animal family members. With this transaction with Elanco, a widely
`respected leader in veterinary medicine with global reach, we will maximize the
`impact our innovative pipeline will have on improving the lives of pets,” said Richard
`Chin, CEO and co-founder of KindredBio.
`
`“This announcement is validation of KindredBio’s achievements as one of the world’s
`first veterinary biopharmaceutical companies, recognizing our track record in drug
`development and remarkably talented team,” added Denise Bevers, Board director and
`co-founder of KindredBio. “KindredBio looks forward to continuing our mission to
`transform veterinary medicine as part of the Elanco family.”
`
`The deal will expand Elanco’s omnichannel leadership complementing the company’s
`e-commerce and retail position by increasing its veterinary clinic presence in a leading
`therapeutic category and keeping the veterinarian at the center. This continues
`Elanco’s work to be a conduit for pet owners to the veterinarian. Dermatologic
`symptoms such as scratching and allergies are the number one reason pet owners visit
`the veterinarian today.
`
`Transaction Details
`
`Under the terms of the agreement, Elanco will acquire all outstanding stock of Kindred
`Biosciences at a price of $9.25 per share, or approximately $440 million, a premium
`of 52% based on the 30-day average. Elanco intends to fund the acquisition with pre-
`payable debt. Elanco expects to extend its leverage objective of under three times net
`leverage to Adjusted EBITDA by three months, from the end of 2023 to the end of the
`first quarter of 2024.
`
`Elanco expects to unlock upside to its long-term growth algorithm, with the potential
`to add a full percentage point of consistent annual revenue growth, starting in 2024,
`and further expand the company’s margin potential over time. Transaction and
`operating costs will be slightly dilutive to Elanco’s reported and adjusted earnings per
`share in 2021, with the impact expected to be concentrated in the fourth quarter, and
`also slightly dilutive to the full year 2022.
`
`“Kindred Biosciences’ monoclonal antibody pipeline and capabilities are additive and
`complementary to what we’ve built within Elanco,” said Aaron Schacht, executive
`vice president Innovation, Regulatory and Business Development at Elanco. “This
`combination will bolster our opportunity for leadership in atopic dermatitis and allow
`
`5
`
`

`

`Case 1:21-cv-01159-UNA Document 1 Filed 08/10/21 Page 6 of 12 PageID #: 6
`
`us to deliver innovation of novel biologic therapeutics to treat other unmet disease
`challenges in pets.”
`
`Elanco expects the transaction to close in the third quarter of 2021, subject to
`customary closing conditions, including approval by KindredBio’s shareholders and
`clearance under the Hart-Scott-Rodino Antitrust Improvements Act. KindredBio’s
`Board approved the proposed acquisition.
`
`Elanco also reaffirmed second quarter 2021 revenue guidance of $1,225 million to
`$1,255 million, and full year 2021 revenue guidance of $4,670 million to $4,710
`million.
`
`Goldman Sachs is acting as financial advisors to Elanco and Covington & Burling LLP
`is acting as legal counsel. Barclays is acting as financial advisor to KindredBio and
`Morrison & Foerster LLP is acting as legal counsel.
`
`The Proxy Statement Contains Material Misstatements and Omissions
`
`21.
`
`The defendants filed a materially incomplete and misleading Proxy Statement with the
`
`SEC and disseminated it to Kindred’s stockholders. The Proxy Statement misrepresents or omits
`
`material information that is necessary for the Company’s stockholders to make an informed decision
`
`whether to vote their shares in favor of the Proposed Transaction.
`
`22.
`
`Specifically, as set forth below, the Proxy Statement fails to provide Company
`
`stockholders with material information or provides them with materially misleading information
`
`concerning: (a) Kindred’s financial forecasts; (b) the financial analyses performed by Kindred’s
`
`financial advisor, Barclays Capital Inc. (“Barclays”), in connection with its fairness opinion; (c)
`
`potential conflicts of interest involving Company management; and (d) the background of the
`
`Proposed Transaction.
`
`Material Omissions Concerning Kindred’s Financial Forecasts
`
`23.
`
`The Proxy Statement omits material information concerning Kindred management’s
`
`financial forecasts, including: (a) all line items underlying (i) Total Revenue, (ii) EBIT, and (iii)
`
`Unlevered Free Cash Flow; and (b) the Company’s net income projections.
`
`24.
`
`This information is material as it provides the Company’s shareholders with a basis
`
`6
`
`

`

`Case 1:21-cv-01159-UNA Document 1 Filed 08/10/21 Page 7 of 12 PageID #: 7
`
`upon which to project the future financial performance of the Company whose stock they are being
`
`asked to surrender in connection with the Proposed Transaction.
`
`25.
`
`The above-referenced omitted information, if disclosed, would significantly alter
`
`the total mix of information available to the Company’s shareholders.
`
`Material Omissions Concerning Barclays’ Financial Analyses
`
`26.
`
`The Proxy Statement also describes Barclays’ fairness opinion and the various
`
`valuation analyses performed in support of their opinions. That description, however, fails to include
`
`key inputs and assumptions underlying these analyses. Without this information, as described below,
`
`Kindred’s public stockholders are unable to fully understand these analyses and, thus, are unable to
`
`determine what weight, if any, to place on Barclays’ fairness opinions in determining whether to vote
`
`in favor of the Proposed Transaction. This omitted information, if disclosed, would significantly alter
`
`the total mix of information available to Kindred’s stockholders.
`
`27. With respect to Barclays’ Discounted Cash Flow Analysis, the Proxy Statement fails
`
`to disclose: (a) the present value of Kindred’s projected after-tax unlevered free cash flows for fiscal
`
`years 2021 (second half) through 2025; (b) the present value of the “terminal value” of Kindred as of
`
`December 31, 2025; (c) The present value of the expected usage of certain federal and state
`
`net operating losses carryforwards and federal and state research and development tax credits; (d) the
`
`specific inputs and assumptions used to determine the utilized annual perpetuity growth rate range
`
`of 3.0% to 5.0%; (e) the specific inputs and assumptions used to determine the utilized discount rate
`
`range of 11.0% to 13.0%; (f) Kindred’s weighted average cost of capital; and Kindred’s estimated net
`
`cash as of June 30, 2021.
`
`28. With respect to Barclays’ Research Analyst Price Targets, the Proxy Statement
`
`fails to disclose: (a) the specific equity targets utilized; and (b) the specific identity of the equity
`
`research analysts that created the equity targets utilized.
`
`7
`
`

`

`Case 1:21-cv-01159-UNA Document 1 Filed 08/10/21 Page 8 of 12 PageID #: 8
`
`29.
`
`The omission of this information renders the statements in the “Opinion of
`
`KindredBio’s Financial Advisor” section of the Proxy Statement false and/or materially misleading
`
`in contravention of the Exchange Act.
`
`Material Omissions Concerning Company Insiders’ Potential Conflicts of Interest
`
`30.
`
`The Proxy Statement fails to disclose material information concerning the conflicts of
`
`interest faced by Company insiders, including the details of any employment and retention-related
`
`discussions and negotiations that occurred between Elanco and Kindred executive officers, including
`
`who participated in all such communications, when they occurred and their content. The Proxy
`
`Statement further fails to disclose whether any of Elanco’s prior proposals or indications of interest
`
`mentioned management retention or equity participation in the combined company.
`
`31.
`
`Communications regarding post-transaction employment and merger-related benefits
`
`during the negotiation of the underlying transaction must be disclosed to stockholders. This
`
`information is necessary for stockholders to understand potential conflicts of interest of management
`
`and the Board, as that information provides illumination concerning motivations that would prevent
`
`fiduciaries from acting solely in the best interests of the Company’s stockholders.
`
`32.
`
`The omission of this information renders the statements in the “Background of the
`
`Merger” and “Interests of the Company’s Directors and Executive Officers in the Merger” sections
`
`of the Proxy Statement false and/or materially misleading in contravention of the Exchange Act.
`
`Material Omissions Concerning the Background of the Proposed Transaction
`
`33.
`
`The Proxy Statement fails to disclose material information concerning the background
`
`process leading to the Proposed Transaction.
`
`34.
`
`The Proxy fails to disclose whether the Company has received requests for waiver or
`
`waived the standstill provisions included in the non-disclosure agreements the Company entered into
`
`with potentially interested parties during its exploration of strategic alternatives, or, if they have not,
`
`8
`
`

`

`Case 1:21-cv-01159-UNA Document 1 Filed 08/10/21 Page 9 of 12 PageID #: 9
`
`whether any standstill provisions that are still in effect currently are precluding these parties from
`
`making a topping bid for the Company.
`
`35.
`
`Any reasonable Kindred stockholder would deem the fact that a likely topping bidder
`
`for the Company may be precluded from making a topping bid for the Company to significantly alter
`
`the total mix of information.
`
`36.
`
`The omission of this material information renders certain portions of the Proxy
`
`materially misleading, including, inter alia, the “Background of the Merger” section.
`
`37.
`
`The Individual Defendants were aware of their duty to disclose the above-referenced
`
`omitted information and acted negligently (if not deliberately) in failing to include this information
`
`in the Proxy Statement. Absent disclosure of the foregoing material information prior to the
`
`stockholder vote on the Proposed Transaction, Plaintiff and the other stockholders of Kindred will be
`
`unable to make a sufficiently informed voting decision in connection with the Proposed Transaction
`
`and are thus threatened with irreparable harm warranting the injunctive relief sought herein.
`
`CLAIMS FOR RELIEF
`
`COUNT I
`
`Claims Against All Defendants for Violations of Section 14(a) of the
`
`Exchange Act and Rule 14a-9 Promulgated Thereunder
`
`Plaintiff repeats all previous allegations as if set forth in full.
`
`During the relevant period, defendants disseminated the false and misleading Proxy
`
`38.
`
`39.
`
`Statement specified above, which failed to disclose material facts necessary to make the statements,
`
`in light of the circumstances under which they were made, not misleading in violation of Section
`
`14(a) of the Exchange Act and SEC Rule 14a-9 promulgated thereunder.
`
`40.
`
`By virtue of their positions within the Company, the defendants were aware of this
`
`information and of their duty to disclose this information in the Proxy Statement. The Proxy
`
`9
`
`

`

`Case 1:21-cv-01159-UNA Document 1 Filed 08/10/21 Page 10 of 12 PageID #: 10
`
`Statement was prepared, reviewed, and/or disseminated by the defendants. It misrepresented and/or
`
`omitted material facts, including material information about (a) Kindred’s financial forecasts; (b) the
`
`financial analyses performed by Barclays; (c) potential conflicts of interest involving Company
`
`management; and (d) the background of the Proposed Transaction. The defendants were at least
`
`negligent in filing the Proxy Statement with these materially false and misleading statements.
`
`41.
`
`The omissions and false and misleading statements in the Proxy Statement are material
`
`in that a reasonable stockholder would consider them important in deciding how to vote on the
`
`Proposed Transaction.
`
`42.
`
`By reason of the foregoing, the defendants have violated Section 14(a) of the Exchange
`
`Act and SEC Rule 14a-9(a) promulgated thereunder.
`
`43.
`
`Because of the false and misleading statements in the Proxy Statement, Plaintiff is
`
`threatened with irreparable harm, rendering money damages inadequate. Therefore, injunctive relief
`
`is appropriate to ensure defendants’ misconduct is corrected.
`
`COUNT II
`
`Claims Against the Individual Defendants for Violations
`of Section 20(a) of the Exchange Act
`
`Plaintiff repeats all previous allegations as if set forth in full.
`
`The Individual Defendants acted as controlling persons of Kindred within the meaning
`
`44.
`
`45.
`
`of Section 20(a) of the Exchange Act as alleged herein. By virtue of their positions as officers and/or
`
`directors of Kindred, and participation in and/or awareness of the Company’s operations and/or
`
`intimate knowledge of the false statements contained in the Proxy Statement filed with the SEC, they
`
`had the power to influence and control and did influence and control, directly or indirectly, the
`
`decision-making of the Company, including the content and dissemination of the various statements
`
`which Plaintiff contends are false and misleading.
`
`10
`
`

`

`Case 1:21-cv-01159-UNA Document 1 Filed 08/10/21 Page 11 of 12 PageID #: 11
`
`46.
`
`Each of the Individual Defendants was provided with or had unlimited access to copies
`
`of the Proxy Statement and other statements alleged by Plaintiff to be misleading prior to and/or
`
`shortly after these statements were issued and had the ability to prevent the issuance of the statements
`
`or cause the statements to be corrected.
`
`47.
`
`In particular, each of the Individual Defendants had direct and supervisory
`
`involvement in the day-to-day operations of the Company, and, therefore, is presumed to have had
`
`the power to control or influence the particular transactions giving rise to the securities violations as
`
`alleged herein and exercised the same. The Proxy Statement at issue contains the unanimous
`
`recommendation of each of the Individual Defendants to approve the Proposed Transaction. They
`
`were, thus, directly involved in the making of the Proxy Statement.
`
`48.
`
`In addition, as the Proxy Statement sets forth at length, and as described herein, the
`
`Individual Defendants were each involved in negotiating, reviewing, and approving the Proposed
`
`Transaction. The Proxy Statement purports to describe the various issues and information that they
`
`reviewed and considered – descriptions into which the Company directors had input.
`
`49.
`
`By virtue of the foregoing, the Individual Defendants have violated Section 20(a) of
`
`the Exchange Act.
`
`50.
`
`As set forth above, the Individual Defendants had the ability to exercise control over
`
`and did control a person or persons who have each violated Section 14(a) and SEC Rule 14a-9,
`
`promulgated thereunder, by their acts and omissions as alleged herein. By virtue of their positions as
`
`controlling persons, these defendants are liable pursuant to Section 20(a) of the Exchange Act. As a
`
`direct and proximate result of defendants’ conduct, Kindred stockholders will be irreparably harmed.
`
`PRAYER FOR RELIEF
`
`WHEREFORE, Plaintiff demands judgment and preliminary and permanent relief, including
`
`injunctive relief, in his favor on behalf of Kindred, and against defendants, as follows:
`
`11
`
`

`

`Case 1:21-cv-01159-UNA Document 1 Filed 08/10/21 Page 12 of 12 PageID #: 12
`
`A.
`
`Preliminarily and permanently enjoining defendants and all persons acting in
`
`concert with them from proceeding with, consummating, or closing the Proposed Transaction and any
`
`vote on the Proposed Transaction, unless and until defendants disclose and disseminate the material
`
`information identified above to Kindred stockholders;
`
`B.
`
`In the event defendants consummate the Proposed Transaction, rescinding it
`
`and setting it aside or awarding rescissory damages to Plaintiff;
`
`C.
`
`Declaring that defendants violated Sections 14(a) and/or 20(a) of the Exchange
`
`Act, as well as SEC Rule 14a-9 promulgated thereunder;
`
`D.
`
`Awarding Plaintiff the costs of this action, including reasonable allowance for
`
`Plaintiff’s attorneys’ and experts’ fees; and
`
`E.
`
`Granting such other and further relief as this Court may deem just and proper.
`
`JURY DEMAND
`
`Plaintiff demands a trial by jury.
`
`Dated: August 10, 2021
`
`
`
`
`
`
`By:
`
`LONG LAW, LLC
`
`/s/ Brian D. Long
`Brian D. Long (#4347)
`3828 Kennett Pike, Suite 208
`Wilmington, DE 19807
`Telephone: (302) 729-9100
`Email: BDLong@longlawde.com
`
`Attorneys for Plaintiff
`
`12
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket